Fig. 1From: The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation studyCumulative incidence curves for prostate cancer-specific survival in the PCBaSe cohort (n = 72,337) stratified by the a Cambridge Prognostic Groups and b current three-strata risk groups as a comparator modelBack to article page